Posts by Cristina Cusin, MD
-
Q&A with Dr. Cristina Cusin: What to Know About Esketamine and Ketamine Treatment
The FDA recently approved Spravato, an intranasal form of esketamine for patients with treatment-resistant depression, which produces improvement hours to days after administration.
-
Effective Ketamine Dosages for Treatment-resistant Depression Identified
Ketamine has long been used as a general anesthetic, but more recent research has found it to be effective in rapidly relieving depression symptoms when given at low, subanesthetic doses. New research identifies two optimal dosages.
Biography
Dr. Cusin went to medical school at the Universita degli Studi, in Milan, Italy, where she also completed a residency in psychiatry. Dr. Cusin was working as psychiatrist in an inpatient unit and involved in research when in 2004 she decided to come to the U.S. for a research fellowship at Mass General.
She decided to pursue further training in the U.S., and after completing the Adult Psychiatry Residency at MGH/McLean she joined the staff of the Depression Clinical & Research Program (DCRP) under the mentorship of Dr. Maurizio Fava.
She is now an assistant professor in psychiatry at Harvard Medical School
Dr. Cusin has an outpatient clinic at the DCRP and often performs consultations for patients with treatment-resistant depression. She is one of the clinicians in the ECT team at Mass General, and she is the primary investigator involved in research studies on ketamine in treatment-resistant mood disorders at Mass General.